Literature DB >> 2886602

Activation of a myenteric 5-hydroxytryptamine-like receptor by metoclopramide.

G J Sanger.   

Abstract

Cholinergically mediated contractions were evoked by electrical field stimulation (EFS) of guinea-pig distal ileum longitudinal muscle-myenteric plexus strips. Metoclopramide, 0.1-100 microM, dose-dependently increased the contractions, probably by increasing acetylcholine (ACh) release; contractions evoked by exogenous ACh in the presence of tetrodotoxin were not increased by metoclopramide. 5-Hydroxytryptamine (5-HT) 0.3-30 nM similarly increased the height of the EFS-evoked contractions, although the maximum increase was less than for metoclopramide; higher concentrations of 5-HT (3 and 30 microM) had no effects or caused inhibition. The compound, ICS 205-930, 0.001-1 microM, had no effect on the EFS-evoked contractions and caused inhibition at higher concentrations. Preincubation of the tissues with 5-HT, 0.3-30 nM, did not affect the increase in EFS-evoked contractions caused by metoclopramide, 1 or 100 microM, whereas 5-HT, 3 and 30 microM, prevented the response caused by metoclopramide 1 microM, but not 100 microM. ICS 205-930, 0.1 microM, had no effect on the increase in EFS-evoked contractions caused by metoclopramide 1 or 100 microM. The drug, at least in low concentrations, may therefore increase cholinergically mediated contractions of guinea-pig ileum by stimulating 5-HT-like receptors within the myenteric plexus, which differ from those antagonized by ICS 205-930.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2886602     DOI: 10.1111/j.2042-7158.1987.tb03418.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  8 in total

1.  Differences between the abilities of tegaserod and motilin receptor agonists to stimulate gastric motility in vitro.

Authors:  E M Jarvie; V J North Laidler; S Corcoran; A Bassil; G J Sanger
Journal:  Br J Pharmacol       Date:  2007-01-08       Impact factor: 8.739

2.  5-Methoxytryptamine and 2-methyl-5-hydroxytryptamine-induced desensitization as a discriminative tool for the 5-HT3 and putative 5-HT4 receptors in guinea pig ileum.

Authors:  D A Craig; R M Eglen; L K Walsh; L A Perkins; R L Whiting; D E Clarke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-07       Impact factor: 3.000

3.  Cisapride and a structural analogue, R 76,186, are 5-hydroxytryptamine4 (5-HT4) receptor agonists on the guinea-pig colon ascendens.

Authors:  M R Briejer; L M Akkermans; A L Meulemans; R A Lefebvre; J A Schuurkes
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-05       Impact factor: 3.000

4.  Azabicycloalkyl benzimidazolone derivatives as a novel class of potent agonists at the 5-HT4 receptor positively coupled to adenylate cyclase in brain.

Authors:  A Dumuis; M Sebben; E Monferini; M Nicola; M Turconi; H Ladinsky; J Bockaert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-03       Impact factor: 3.000

5.  Pharmacological analysis of 5-hydroxytryptamine effects on electrically stimulated human isolated urinary bladder.

Authors:  M Corsi; C Pietra; G Toson; D Trist; G Tuccitto; W Artibani
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

6.  Regionally selective cholinergic stimulation by BRL 24924 in the human isolated gut.

Authors:  T A Burke; G J Sanger
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

7.  Characterization of a novel 5-HT4 receptor antagonist of the azabicycloalkyl benzimidazolone class: DAU 6285.

Authors:  A Dumuis; H Gozlan; M Sebben; H Ansanay; C A Rizzi; M Turconi; E Monferini; E Giraldo; P Schiantarelli; H Ladinsky
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-03       Impact factor: 3.000

Review 8.  A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research.

Authors:  Gareth J Sanger; Paul L R Andrews
Journal:  Front Pharmacol       Date:  2018-09-04       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.